{
    "nctId": "NCT02209857",
    "briefTitle": "The Symphony Triple A Study: Using Symphony in Treatment Decisions Concerning Adjuvant Systemic Therapy",
    "officialTitle": "The Symphony Triple A Study: Using Symphony as an Adjunct to Histopathologic Parameters When the Doctor is Ambivalent About the Administration and Type of Adjunctive Systemic Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breastcancer, Invasive Breast Carcinoma by Gene Expression Profile",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 660,
    "primaryOutcomeMeasure": "Frequency of adjuvant chemotherapy",
    "eligibilityCriteria": "Inclusion criteria\n\n* Oestrogen receptor positive, invasive ductal and female breast cancer patients where the benefit of adjuvant chemotherapy is uncertain based on traditional prognostic factors\n* Written informed consent\n* Patients with multicentric or contralateral disease\n\nExclusion criteria\n\n* Patients with a previous history of malignancy (in the five years before breast cancer diagnosis), excluding basal cell carcinoma.\n* Patients with confirmed distant metastasis.\n* Patients who undergo neoadjuvant systemic treatment.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}